Specialized Research

B7-33

Also known as: Relaxin-2 mimetic, Mimético de Relaxina-2

Molecular Identifiers

Molecular Formula

C131H229N41O36S

CAS Number

1818415-56-3

PubChem CID

318164840

Molecular Weight

2986.54 Da

Overview

Single-chain mimetic peptide of human relaxin-2, designed to selectively activate the RXFP1 receptor. Unlike native relaxin-2 which has a two-chain structure, B7-33 consists of a single chain derived from the B-chain of relaxin, simplifying production while maintaining anti-fibrotic and vasodilatory biological activity.

Sequence (1 letter): VIKLSGRELVRAQIAISGMSTWSKRSL

Extended notation: Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu

Single-chain peptide — relaxin-2 mimetic with simplified structure

Half-life

~1-2 hours

Administration Route

Subcutaneous

Mechanism of Action

Selective agonism of the RXFP1 receptor (relaxin family peptide receptor 1)
Anti-fibrotic effect via inhibition of collagen deposition and extracellular matrix remodeling
Vasodilation mediated by nitric oxide (NO) and endothelin
Reduction of tissue inflammation and fibrosis in target organs
Modulation of TGF-β signaling and pro-fibrotic pathways

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter	Value
Dose	100-500 mcg per injection (subcutaneous)
Frequency	Once daily
Timing	Per clinical guidance
Duration	4-8 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

Mild hypotension
Headache
Facial flushing

Product Properties

Purity	>98%
Appearance	White lyophilized powder
Solubility	Soluble in water and bacteriostatic water
Source	Solid-phase peptide synthesis (SPPS)
Storage	Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 2 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.